Critical appraisal:Sur RL, Borboroglu PG, Roberts JL, Amling CL 2004 2
From Cancer Guidelines Wiki
Risk of bias assessment: randomised controlled trial
Was the trial double-blinded?
- Outcomes not blinded, substantial side-effects, or not reported.
Was the treatment allocation schedule concealed?
- No concealment or unclear (e.g. no approach described, open randomisation lists, person doing recruitment tossing a coin).
Were all randomised participants included in the analysis?
- Too many exclusions, differential loss in comparison groups, or not reported.
The field below is not considered when calculating the risk of bias rating
Overall risk of bias
High risk of bias | Additional comments: Please replace this text and include any additional comments in regards to your quality rating |
- Article
- Sur RL, Borboroglu PG, Roberts JL, Amling CL. A prospective randomized comparison of extensive prostate biopsy to standard biopsy with assessment of diagnostic yield, biopsy pain and morbidity. Prostate Cancer Prostatic Dis 2004;7(2):126-31 Available from: http://www.ncbi.nlm.nih.gov/pubmed/15111980.
- Assigned to
- User:Cindy.peng
- Topic area
- Guidelines:PSA Testing
- Clinical question
Section below only relevant for Cancer Council Project Officer